日韩成人一区二区三区在线观看,亚洲爆乳成av人在线视菜奈实,一级特黄aaa大片在线观看成人一级片在线观看,欧美一级a视频在线观看,久久综合狠狠色综合伊人,国产亂倫近親相姦视频,日韩免费无码视频一区二区三区,97久久精品亚洲中文字幕无码,久爱无码精品免费视频,超碰97人人模人人爽人人

Recombinant Protein
Home > Application > Recombinant Protein > Insulin

Insulin


Diabetes is a global disease affecting more than 420 million people (6% of the world's population), a number that is expected to balloon to 500 million by 2030 and 700 million by 2045. The increase in the number of diabetic patients worldwide will lead to a consequent increase in the need for insulin. Furthermore, there is an unmet need for affordable insulin, especially in low- and middle-income countries. Many people with type 1 diabetes who live entirely on insulin do not have access to insulin. Of the 60 million people with type 2 diabetes who require insulin therapy, one in two do not have access to insulin because of price (WHO 2021).

 

Injectable insulin is important in the treatment of both type 1 and type 2 diabetes, and recombinant human insulin has been shown to offer significant advantages over extracted insulin. For the production of insulin, two different production methods have been reported. In the first method, the A and B chains of insulin are cultured separately in bacteria as inclusion bodies. Then, the two chains are purified separately, then chemically joined, followed by a final purification step. In the second technique, proinsulin is expressed in E. coli in the form of a tryptophan promoter with methionine linked to proinsulin. Cyanogen bromide (CNBr) is used to cleave the linkage, then form the folded peptide through the correct disulfide bonds, and finally enzymatically eliminate the C-peptide. The "proinsulin route" is preferred because it requires only a single fermentation and purification procedure, and the production process is more efficient compared to the two-chain combinatorial approach.

 

In addition to using bacteria as a host system, yeast is also used for the commercial production of insulin. The main yeast strains used commercially are Saccharomyces cerevisiae and Pichia pastoris. The yeast-based expression system produces a soluble insulin precursor that is secreted into the culture supernatant. There are pros and cons to using bacteria and yeast as expression systems. Production of precursor insulin via the bacterial inclusion body pathway generally results in higher product concentrations and productivity. Compared to soluble expression of bioactive therapeutic proteins, inclusion bodies have good mechanical stability and are resistant to proteolytic degradation. In terms of downstream purification, target proteins in inclusion bodies are also isolated in a purer and more concentrated state compared to secreted proteins, which require removal of large amounts of host cell protein impurities from culture supernatants. Peptides are also easier to isolate from inclusion bodies due to their different sizes and densities compared to host proteins.

 

The use of Escherichia coli as an expression system for large-scale recombinant insulin production has the advantages of high growth rate, simple media requirements, easy for operation, high yield, and cost-effectiveness. E. coli is also well characterized genetically, and a large number of mutant host strains and cloning vectors are available. However, the inclusion body production pathway in E. coli requires complex processing, such as solubilization and refolding procedures, to obtain fully functional polypeptides. For most biopharmaceutical companies, Escherichia coli remains the host system of choice for the production of recombinant insulin, with human insulin and its analogs expressed in inclusion bodies in most cases. Insulin analogs are synthetically produced variants of insulin whose amino acid sequence differs from native human insulin. Such changes have been made to more closely mimic the normal physiological pattern of insulin secretion in humans.

 

The single-chain insulin precursor molecule in E. Coli inclusion bodies was mostly misfolded. Inclusion bodies are extracted from cells, washed, and the precursor molecules are solubilized. The production of proinsulin requires peptide folding and the concomitant formation of disulfide bonds. After an enzymatic reaction, the refolded precursor molecule is converted into a heterodimeric insulin molecule by removal of the C-chain and N-terminal fusion peptide. Various chromatographic purification steps are required to remove host cell proteins, nucleic acids, membrane debris, and digestion by-products to yield highly purified products.

 

The downstream process for purification of recombinant human insulin/analogues from E. coli inclusion bodies is complex, involves multiple steps, and details of the processes established by different companies are often proprietary. The method used in each step will have a major impact on the product purity and yield in the next step, so in-depth consideration and research should be done during development and optimization.




None

None

Related Products
Contact Us
  • Tel.: +86 021 6434 0155
  • E-Mail: marketing@duoningbio.com
  • Address: Building 30, No. 1525 Minqiang Road, Songjiang District, Shanghai
Message

Copyright ? Shanghai Duoning Biotechnology Co., Ltd. All Rights Reserved Sitemap | Technical Support: Reanod

WeChat
WeChat

Message-

Duoning Biotechnology

+86 021 6434 0155

国产乱子伦精品免费无码专区| 麻豆国产VA免费精品高清在线,| 国产初高中生真实在线视频| 国产精品亚洲二区在线观看| 国产VA免费精品高清在线观看| AWWW在线天堂BD资源在线| 99国产精品久久久久久久成人热| 日韩中文字幕无码精品视频| 四虎国产精品永久地址99| 国产女人的高潮国语对白入口| 中文字幕一级黄色电影| 91精品国久久久久久无码免费| 国产精品自产拍在线观看| 国产精品天天看特色大片互動交流| 狠狠躁天天躁中文字幕天码| 97人人看碰人免费公开视频| 无码制服丝袜人妻在线视频| 国产AⅤ无码专区久久精品国产| 国产在线午夜不卡精品影| 亚洲欧美日韩国产成人一区| 无码少妇久久精品| 欧美人与动性xxxxx杂性| 精品国产乱码久久久久久蜜桃免费| 欧美疯狂做受XXXX高潮| 国产va成人无码人在线观看天堂| 又黄又爽又无遮挡免费的网站| 久久精品午夜一区二区福利| 国产一级三级毛片| 人妻少妇看A偷人无码| 免费人妻av无码专区| 欧美精品v欧洲精品| 精品视频在线观看一区二区三区| 丰满少妇无套内射一区| 满少妇高潮惨叫久久久| 精品人妻系列无码人妻漫画| 久青草国产在视频在线观看| 青草视频在线播放| 久久一二日韩欧美综合网| 亚洲人成免费在线| 一区二区天堂资源中文最新版在线一区| 成人AV鲁丝片一区二区免费|